Axitinib: Additional Phase III data

Additional data from the open-label, international Phase III AXIS 1032 trial in 723 patients showed that twice-daily oral axitinib as second-line therapy significantly improved median PFS, the primary endpoint, vs. twice-daily sorafenib (6.7 vs. 4.7 months, p<0.0001). Axitinib also met the secondary endpoint of significantly increasing ORR vs. sorafenib (19.4% vs. 9.4%, p=0.0001). Data are being presented at the American Society of Clinical Oncology meeting in Chicago. ...